RenovoRx Earnings Call Highlights Record Growth

RenovoRx (RNXT) reported Q3 2026 revenue of $1.07M, up 17% QoQ and 300% YoY. It has 26 active commercial cancer centers and expects 36 by year-end. Phase III trial enrollment is complete, with results expected in 2H 2027. The company faces net losses and higher expenses but remains optimistic about growth.

Original reporting
Published Nov 15, 2026, 2:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 12:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RNXT
Neutral
high confidence
Mentioned
$RNXT
Relevance
4/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$RNXTNeutralLow
01

Why it matters

The article repeats previously disclosed numbers; no new catalyst for price action.

02

Market read

A straightforward earnings recap with no fresh data; limited trading relevance.

03

What to watch

None; the piece offers no additional insight beyond the prior release.

Relevance 4/10Novelty 2/10Timing: post‑earnings recap

Background

RenovoRx (RNXT) reported Q3 2026 results with record revenue of $1.07 M, 82% gross margin, and maintained 2026 revenue guidance of $3.75‑$4.25 M.

Company-level read

Ticker impact

$RNXTNeutralHigh confidence
Context

The article recaps RenovoRx's Q3 2026 earnings call, repeating revenue, loss and guidance figures already released on 2026-11-05.

Expected impact

likely little to no price movement as the information is already public

Evidence & confidence

All financial metrics and guidance were disclosed in the prior earnings release; the article adds no fresh data.

Market effects

None; the biotech sector receives no new development from this recap.

None; the article is US‑focused but adds no regional shift.

Low; no broader market impact.

Counterpoint

None; no contrary angle presented.

Key entities

  • RenovoRx

    Biotech firm developing the TAMP platform for pancreatic cancer.

Related articles

$RNXTMed

RenovoRx Inc (RNXT) (Q3 2026) Earnings Call Highlights: Record Revenue, Expanding

RenovoRx Inc (RNXT) reported Q3 2026 record revenue of $1.07M, up 17% sequentially. CEO Sean Bagai discussed potential impacts of Razin-Q approval on pancreatic cancer treatment and commercialization plans. The company has 26 active commercial centers, with a target of 36 by year-end. Phase III TIGER-PACT trial data is expected in H2 2027. Gross margin was 82%, and cash position is $10.4M. Full-year 2026 revenue guidance remains $3.75M-$4.25M.

$RNXTMed

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel…

RenovoRx, Inc. (RNXT) filed an SEC Form 8-K — Results of Operations and Financial Condition. RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel Grows to More Than 65 Centers Maintains 2026 Annual Revenue Guidance of $3.75M to $4.25M First Physician-Driven Expansion

$RNXTMedAI 8/10

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx (Nasdaq: RNXT) announced the first patient has enrolled in the PRISM-TAMP trial, evaluating its TAMP platform for borderline resectable pancreatic cancer. The trial, sponsored by the University of Vermont, aims to assess tumor regression and safety. RenovoRx reported $1.1M in 2025 RenovoCath sales and $909K in Q2 2026. The company expects topline data from its Phase III TIGeR-PaC trial in late 2027.

$RNXTMedAI 8/10

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) announced a peer-reviewed publication in Case Reports in Oncology. The study, led by researchers at Hackensack Meridian Health, showed promising results for two locally advanced pancreatic cancer patients treated with the company's TAMP platform and RenovoCath device. The patients experienced tumor responses and reductions in CA 19-9 markers.